Most Recent
Pharmacy giant Priceline is the target of an "imminent" class action, with a group of dissatisfied franchisees accusing the company of exercising an "overly prescriptive" level of control over its franchises and fettering profitability.
The former chief financial officer of delisted Traditional Therapy Clinics has appeared in court after pleading guilty to market manipulation charges relating to transactions intended to create an artificial share price for the traditional therapy clinic company.
A judge has refused to disqualify herself from hearing a complex medical negligence lawsuit after she described an expert conclave as a "car crash", citing concerns over a psychiatrist giving opinions about liability in a surgical setting.
COVID-19 vaccinations will begin this week, but most employers won't be able to force staff to get the jab.
Fertility clinic IVF Australia is facing a lawsuit worth "many millions of dollars" launched by the parents of a child born with Pallister-Kilian syndrome, alleging it did not carry out a vital pre-implantation diagnostic test that would have identified the disease.
Pharmaceutical companies Sanofi and Bristol-Myers Squibb are liable for losses to the federal government for excess subsidies it allegedly paid for the blood-thinner Plavix after an unjustified court injunction prevented the release of a generic version of the top-selling drug, an appeals court has heard.
A $37.75 million settlement has been reached in a shareholder class action against Estia Health that accused the aged care provider of failing to disclose difficulties in its 2015 and 2016 acquisition strategy.
US pharmaceutical giant Merck Sharp & Dohme has taken Sandoz to court for allegedly threatening to infringe the patent for its multibillion-dollar diabetes drugs Janumet and Januvia.
US biotech company Gen-Probe's bid for the removal of rival Beckman Coulter's 'Access' trade marks will be heard alongside its appeal of a ruling from the Trade Marks Office denying the company's bid to expand its 'Open Access' trade mark to Australia.
The High Court will decide whether the Full Court was wrong to overturn a $26.3 million judgment for Danish drug maker H Lundbeck in its long-running patent battle with generic drug maker Sandoz over the patent for blockbuster antidepressant Lexapro.